Henry Schein's broader growth, recurring technology revenues and savings plan support its outlook, but leverage and execution risks remain key concerns.
Henry Schein's stronger Q2 sales and margins prompt a 2026 outlook hike, but second-half savings execution remains key to sustaining earnings momentum.
Empowered Funds LLC lessened its stake in Henry Schein, Inc. (NASDAQ: HSIC) by 59.2% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 11,551 shares of the company's stock after selling 16,735 shares during the period. Empowered Funds LLC's holdings in Henry Schein
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Investors with an interest in Medical - Dental Supplies stocks have likely encountered both Henry Schein (HSIC) and Straumann Holding AG (SAUHY). But which of these two stocks presents investors with the better value opportunity right now?